STRYKER CORP (SYK) Form 10-Q — Oct 30, 2026
Stryker reported Q3 2026 net sales growth of 7.7% (6.4% organic) with adjusted diluted EPS of $3.52 for the quarter, up 7.1% year over year, driven by unit volume across MedSurg…
Key figures
- Net Income
- 2774
- Total Assets
- 47247
- Cash Position
- 3271
- Shares Outstanding
- 380691004
- Avs milestones
- 400
- Q3 net earnings
- 753
- Q3 sales growth
- 7.7%
- Buyback increase
- 3000
- Dividends paid 9m
- 1012
- Q3 organic growth
- 6.4%
- Q3 repurchase cost
- 1000
- Goodwill impairment
- 293
- Q3 operating margin
- 15.9%
- Avg repurchase price
- 334.46
- Avs acquisition cash
- 434
- Q3 shares repurchased
- 3
- Operating cash flow 9m
- 3303
- Cmr surgical investment
- 400
- Nine month sales growth
- 6.6%
- Q3 adjusted diluted eps
- 3.52
- Q3 reported diluted eps
- 1.96
- Impairment unit goodwill
- 3259
- Total buyback authorization
- 3033
- Nine month adjusted net earnings
- 3785
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.